(FTV) Fortive - Ratings and Ratios
Instruments, Software, Sensors, Sterilizers, Trackers
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 0.54% |
| Yield on Cost 5y | 0.64% |
| Yield CAGR 5y | 4.19% |
| Payout Consistency | 98.6% |
| Payout Ratio | 7.8% |
| Risk via 5d forecast | |
|---|---|
| Volatility | 23.1% |
| Value at Risk 5%th | 36.2% |
| Relative Tail Risk | -4.88% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.18 |
| Alpha | -23.09 |
| CAGR/Max DD | 0.13 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.297 |
| Beta | 0.948 |
| Beta Downside | 1.101 |
| Drawdowns 3y | |
|---|---|
| Max DD | 28.01% |
| Mean DD | 11.43% |
| Median DD | 11.17% |
Description: FTV Fortive January 03, 2026
Fortive Corp (NYSE:FTV) is a diversified industrial-technology company that designs, manufactures and markets products, software and services across the United States, China and other global markets. It operates through two primary segments: Intelligent Operating Solutions (IOS) and Advanced Healthcare Solutions (AHS).
The IOS segment delivers advanced instrumentation, test-and-measurement equipment, lifecycle-management software and connected-worker safety tools for manufacturers, process industries, utilities, communications and electronics firms. Key brands include ACCRUENT, FLUKE, GORDIAN, INDUSTRIAL SCIENTIFIC, INTELEX, PRUFTECHNIK and SERVICECHANNEL.
The AHS segment focuses on critical workflow solutions for the medical-device and clinical-care ecosystem, offering instrument sterilization, tracking, cell-therapy hardware, biomedical test tools, radiation-safety monitoring and end-to-end clinical productivity software. Prominent brands are ASP, CENSIS, CENSITRAC, EVOTECH, FLUKE BIOMEDICAL, INVETECH, LANDAUER, PROVATION, RAYSAFE and STERRAD.
Recent financials (FY 2023) show revenue of roughly $5.6 billion, up 4 % YoY, with an adjusted EBITDA margin of ~15 % and free cash flow generation of $550 million, reflecting steady demand for automation-driven solutions and resilient healthcare-equipment spending despite macro-uncertainty.
Key economic drivers for Fortive include the ongoing industrial automation wave, which is projected to grow at a 6-7 % CAGR through 2028, and the expanding global market for sterile processing and cell-therapy equipment, a segment that is expected to outpace overall healthcare-equipment growth by 2-3 pp annually.
Investors should watch the company’s ability to capture share-of-wallet in the “connected worker” safety market (estimated $12 billion TAM) and its progress on high-margin software-as-a-service contracts, which historically deliver >20 % recurring-revenue growth.
For a deeper quantitative view, consider exploring ValueRay’s proprietary valuation metrics on Fortive to assess whether the current price reflects its long-term growth potential.
Piotroski VR‑10 (Strict, 0-10) 8.5
| Net Income (602.3m TTM) > 0 and > 6% of Revenue (6% = 338.4m TTM) |
| FCFTA 0.09 (>2.0%) and ΔFCFTA 1.35pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -13.08% (prev 8.63%; Δ -21.71pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.10 (>3.0%) and CFO 1.19b > Net Income 602.3m (YES >=105%, WARN >=100%) |
| Net Debt (2.88b) to EBITDA (1.39b) ratio: 2.07 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.70 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (333.4m) change vs 12m ago -5.36% (target <= -2.0% for YES) |
| Gross Margin 60.33% (prev 59.74%; Δ 0.59pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 38.45% (prev 35.50%; Δ 2.95pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 7.55 (EBITDA TTM 1.39b / Interest Expense TTM 122.6m) >= 6 (WARN >= 3) |
Altman Z'' 2.49
| (A) -0.06 = (Total Current Assets 1.73b - Total Current Liabilities 2.47b) / Total Assets 11.89b |
| (B) 0.44 = Retained Earnings (Balance) 5.26b / Total Assets 11.89b |
| (C) 0.06 = EBIT TTM 925.7m / Avg Total Assets 14.67b |
| (D) 0.99 = Book Value of Equity 5.30b / Total Liabilities 5.38b |
| Total Rating: 2.49 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 57.71
| 1. Piotroski 8.50pt |
| 2. FCF Yield 5.04% |
| 3. FCF Margin 19.18% |
| 4. Debt/Equity 0.51 |
| 5. Debt/Ebitda 2.07 |
| 6. ROIC - WACC (= -2.04)% |
| 7. RoE 6.46% |
| 8. Rev. Trend -11.92% |
| 9. EPS Trend -48.70% |
What is the price of FTV shares?
Over the past week, the price has changed by -1.39%, over one month by -1.21%, over three months by +12.68% and over the past year by -4.08%.
Is FTV a buy, sell or hold?
- Strong Buy: 6
- Buy: 5
- Hold: 9
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the FTV price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 57.6 | 5.4% |
| Analysts Target Price | 57.6 | 5.4% |
| ValueRay Target Price | 55.3 | 1.1% |
FTV Fundamental Data Overview January 13, 2026
P/E Forward = 19.4553
P/S = 2.9725
P/B = 2.6859
P/EG = 1.2896
Beta = 1.042
Revenue TTM = 5.64b USD
EBIT TTM = 925.7m USD
EBITDA TTM = 1.39b USD
Long Term Debt = 2.12b USD (from longTermDebt, last quarter)
Short Term Debt = 1.19b USD (from shortTermDebt, last quarter)
Debt = 3.31b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.88b USD (from netDebt column, last quarter)
Enterprise Value = 21.48b USD (18.61b + Debt 3.31b - CCE 430.8m)
Interest Coverage Ratio = 7.55 (Ebit TTM 925.7m / Interest Expense TTM 122.6m)
EV/FCF = 19.86x (Enterprise Value 21.48b / FCF TTM 1.08b)
FCF Yield = 5.04% (FCF TTM 1.08b / Enterprise Value 21.48b)
FCF Margin = 19.18% (FCF TTM 1.08b / Revenue TTM 5.64b)
Net Margin = 10.68% (Net Income TTM 602.3m / Revenue TTM 5.64b)
Gross Margin = 60.33% ((Revenue TTM 5.64b - Cost of Revenue TTM 2.24b) / Revenue TTM)
Gross Margin QoQ = 63.21% (prev 58.97%)
Tobins Q-Ratio = 1.81 (Enterprise Value 21.48b / Total Assets 11.89b)
Interest Expense / Debt = 0.77% (Interest Expense 25.4m / Debt 3.31b)
Taxrate = 13.33% (18.0m / 135.0m)
NOPAT = 802.3m (EBIT 925.7m * (1 - 13.33%))
Current Ratio = 0.70 (Total Current Assets 1.73b / Total Current Liabilities 2.47b)
Debt / Equity = 0.51 (Debt 3.31b / totalStockholderEquity, last quarter 6.50b)
Debt / EBITDA = 2.07 (Net Debt 2.88b / EBITDA 1.39b)
Debt / FCF = 2.66 (Net Debt 2.88b / FCF TTM 1.08b)
Total Stockholder Equity = 9.33b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.11% (Net Income 602.3m / Total Assets 11.89b)
RoE = 6.46% (Net Income TTM 602.3m / Total Stockholder Equity 9.33b)
RoCE = 8.09% (EBIT 925.7m / Capital Employed (Equity 9.33b + L.T.Debt 2.12b))
RoIC = 6.05% (NOPAT 802.3m / Invested Capital 13.25b)
WACC = 8.09% (E(18.61b)/V(21.91b) * Re(9.41%) + D(3.31b)/V(21.91b) * Rd(0.77%) * (1-Tc(0.13)))
Discount Rate = 9.41% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -3.02%
[DCF Debug] Terminal Value 79.13% ; FCFF base≈1.19b ; Y1≈1.31b ; Y5≈1.68b
Fair Price DCF = 80.83 (EV 28.55b - Net Debt 2.88b = Equity 25.67b / Shares 317.6m; r=8.09% [WACC]; 5y FCF grow 11.56% → 2.90% )
EPS Correlation: -48.70 | EPS CAGR: -19.51% | SUE: 0.11 | # QB: 0
Revenue Correlation: -11.92 | Revenue CAGR: -7.48% | SUE: 0.11 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.63 | Chg30d=+0.001 | Revisions Net=+2 | Analysts=10
EPS next Year (2026-12-31): EPS=2.84 | Chg30d=-0.008 | Revisions Net=+0 | Growth EPS=+7.4% | Growth Revenue=+3.1%
Additional Sources for FTV Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle